Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

SML1928

Sigma-Aldrich

UM-164 trifluoroacetate salt

≥98% (HPLC)

Synonym(s):

2-[[6-[4-(2-Hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-5-thiazolecarboxamide trifluoroacetate salt

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C30H31F3N8O3S · xC2HF3O2
CAS Number:
903564-48-7
Molecular Weight:
640.68 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: 10 mg/mL, clear

storage temp.

2-8°C

SMILES string

OCCN(CC1)CCN1C2=CC(NC3=NC=C(C(NC4=CC(NC(C5=CC(C(F)(F)F)=CC=C5)=O)=CC=C4C)=O)S3)=NC(C)=N2

Biochem/physiol Actions

UM-164 is a potent dual c-Src/p38 kinase inhibitor that exhibits potent anti-TNBC activity in xenograft models. UM-164 inhibits p38 kinase and binds to an inactive c-Src conformation. UM-164 has a high therapeutic index in vivo.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H315,H319

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Frank E Kwarcinski et al.
ACS chemical biology, 11(5), 1296-1304 (2016-02-20)
In the kinase field, there are many widely held tenets about conformation-selective inhibitors that have yet to be validated using controlled experiments. We have designed, synthesized, and characterized a series of kinase inhibitor analogues of dasatinib, an FDA-approved kinase inhibitor
Rabia A Gilani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 22(20), 5087-5096 (2016-05-08)
c-Src has been shown to play a pivotal role in breast cancer progression, metastasis, and angiogenesis. In the clinic, however, the limited efficacy and high toxicity of existing c-Src inhibitors have tempered the enthusiasm for targeting c-Src. We developed a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service